Table 3.
Synergy factor analysis.
| Genes | Genotypes | Synergy factora | p-valueb | Type interactiona |
|---|---|---|---|---|
| SOD2 × CAT | TT–TT | – | – | – |
| SOD2 × GPX4 | TT–CC | 1.18 | 0.89 | Antagonistic |
| SOD2 × NOS1 | TT–TT | 0.80 | 0.84 | Antagonistic |
| SOD2 × NOS2 | TT–TT | – | – | – |
| GPX4 × CAT | CC–TT | 0.13 | 0.26 | Synergistic |
| GPX4 × NOS1 | CC–TT | 0.18 | 0.16 | Synergistic |
| GPX4 × NOS2 | CC–TT | – | – | – |
| NOS1-CAT | TT–TT | – | – | – |
| NOS1 × NOS2 | TT–TT | 0.02 | < 0.01 | Synergistic, protectivec |
| NOS2 × CAT | TT–TT | – | – | – |
p < 0.05 s are bold and in bold for the genotypes with a protective effect.
aAll SF relate to the risk of MS. The cited genotypes were treated as risk factors, unless otherwise stated; the terms, ‘risk’ and ‘protective’ factors, refer to associations, i.e. no causality is implied. Note that synergy (antagonism) between risk factors will produce a SF > 1 (< 1), while synergy (antagonism) between protective factors will give a SF < 1 (> 1).
bAll p-values are before correction for multiple testing, whether or not relevant.